Clinical Trials Browser

Meningeal Carcinomatosis

NCT07348965 2026-01-16

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Phase NA Not yet recruiting

42 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT07199413 2025-09-30

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Phase 1 Not yet recruiting

20 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT07177950 2025-09-17

A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases

Phase 1/2 Not yet recruiting

51 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Meningeal Carcinomatosis

NCT06984523 2025-05-25

Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis

Phase NA Not yet recruiting

20 enrolled

CNS

Meningeal Carcinomatosis

NCT06971406 2025-05-14

FLAME-1

Phase 2 Not yet recruiting

100 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06861218 2025-03-06

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Phase 2 Not yet recruiting

42 enrolled

CNS

Meningeal Carcinomatosis

NCT06766591 2025-01-09

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Phase NA Not yet recruiting

36 enrolled

CNS

Meningeal Carcinomatosis

NCT06441045 2024-06-04

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Phase 2 Not yet recruiting

112 enrolled

CNS

Meningeal Carcinomatosis

NCT05805631 2024-05-01

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Phase 2 Not yet recruiting

23 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06282874 2024-02-28

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Phase 4 Not yet recruiting

50 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Clinical Trials

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases

Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis

FLAME-1

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases